Ruth O'Regan, MD
As biosimilars inch closer to the market, conversations around cost have taken center stage. In other markets across the world, biosimilars have reduced costs in oncology—both for payers and patients.
Ruth O’Regan, MD, professor of medicine at University of Wisconsin School of Medicine and Carbone Cancer Center, discussed the excitement with biosimilars, and the potential impact they could have on the US drug market.
OncLive: Can you share your thoughts on biosimilars in breast cancer?
: Biosimilars really are beginning to take off in oncology. For breast cancer, we have seen data on trastuzumab biosimilars. We have randomized studies where they have been compared with trastuzumab, showing similar safety and immunogenicity. They are pretty much ready for primetime. It is going to be interesting because the data suggest that they are identical, but whether patients who have been on trastuzumab for metastatic disease for years will be accepting of this change—we don't know at this time.
... to read the full story